TECX (Tectonic Therapeutic, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TECX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | Marcella K. Ruddy | Chief Medical Officer | A | — | — |
| 2026-09-08 | Daniel Lochner | Chief Financial Officer | A | — | — |
| 2026-09-08 | Marc Schwabish | Chief Business Officer | A | — | — |
| 2026-09-08 | ALISE REICIN | Chief Executive Officer | A | — | — |
| 2026-09-08 | Peter McNamara | Chief Scientific Officer | A | — | — |
| 2026-08-26 | Peter McNamara | Chief Scientific Officer | MIXED | — | — |
| 2026-08-14 | Peter McNamara | Chief Scientific Officer | MIXED | — | — |
| 2026-07-01 | Peter McNamara | Chief Scientific Officer | MIXED | — | — |
| 2026-06-23 | ALISE REICIN | Chief Executive Officer | F | — | — |
| 2026-06-12 | Daniel Lochner | Chief Financial Officer | A | — | — |
| 2026-06-10 | TIMOTHY A SPRINGER | Director | A | — | — |
| 2026-06-10 | Praveen P. Tipirneni | Director | A | — | — |
| 2026-06-10 | Stefan Vitorovic | Director | A | — | — |
| 2026-06-10 | Jessica Caroline Chutter | Director | A | — | — |
| 2026-06-10 | Phillip B. Donenberg | Director | A | — | — |
| 2026-05-06 | Marcella K. Ruddy | Chief Medical Officer | Sell | — | — |
| 2026-04-03 | Francois Nader | Director | A | — | — |
| 2026-04-03 | Marcella K. Ruddy | Chief Medical Officer | Sell | — | — |
| 2026-03-09 | Marcella K. Ruddy | Chief Medical Officer | Sell | — | — |
| 2026-03-09 | Peter McNamara | Chief Scientific Officer | MIXED | — | — |
| 2026-03-05 | Marcella K. Ruddy | Chief Medical Officer | A | — | — |
| 2026-03-05 | ALISE REICIN | Chief Executive Officer | Buy | — | — |
| 2026-03-05 | Daniel Lochner | Chief Financial Officer | A | — | — |
| 2026-03-05 | Marc Schwabish | Chief Business Officer | A | — | — |
| 2026-03-05 | Peter McNamara | Chief Scientific Officer | MIXED | — | — |
| 2026-03-05 | ALISE REICIN | Chief Executive Officer | A | — | — |
| 2026-02-12 | Marc Schwabish | Chief Business Officer | M | — | — |
| 2026-02-12 | ALISE REICIN | Chief Executive Officer | Buy | — | — |
| 2026-02-11 | Daniel Lochner | Chief Financial Officer | Buy | — | — |
| 2026-02-10 | Daniel Lochner | Chief Financial Officer | F | — | — |
| 2026-02-10 | Marcella K. Ruddy | Chief Medical Officer | F | — | — |
| 2026-02-10 | Marc Schwabish | Chief Business Officer | F | — | — |
| 2026-02-10 | Peter McNamara | Chief Scientific Officer | F | — | — |
| 2026-02-10 | ALISE REICIN | Chief Executive Officer | F | — | — |
| 2026-01-05 | ALISE REICIN | Chief Executive Officer | M | — | — |
| 2025-12-29 | Peter McNamara | Chief Scientific Officer | M | — | — |
| 2025-09-29 | Marcella K. Ruddy | Chief Medical Officer | A | — | — |
| 2025-09-29 | Daniel Lochner | Chief Financial Officer | A | — | — |
| 2025-09-29 | ALISE REICIN | Chief Executive Officer | A | — | — |
| 2025-09-29 | Peter McNamara | Chief Scientific Officer | A | — | — |
| 2025-09-29 | Marc Schwabish | Chief Business Officer | A | — | — |
| 2025-06-24 | ALISE REICIN | Chief Executive Officer | F | — | — |
| 2025-06-11 | Praveen P. Tipirneni | Director | A | — | — |
| 2025-06-11 | TERRANCE MCGUIRE | Director | A | — | — |
| 2025-06-11 | Stefan Vitorovic | Director | A | — | — |
| 2025-06-11 | Phillip B. Donenberg | Director | A | — | — |
| 2025-06-11 | TIMOTHY A SPRINGER | Director | A | — | — |
| 2025-04-11 | TIMOTHY A SPRINGER | Director | Buy | — | — |
| 2025-04-09 | TIMOTHY A SPRINGER | Director | Buy | — | — |
| 2025-04-07 | TERRANCE MCGUIRE | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 5,724,306 | — |
| — | Chief Executive Officer | 437,653 | — |
| — | Chief Medical Officer | 67,682 | — |
| — | Chief Financial Officer | 58,544 | — |
| — | Chief Scientific Officer | 55,285 | — |
| — | Chief Business Officer | 45,314 | — |
| — | Director | 20,262 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TECX quote page; the site-wide leaderboard is on the insider transactions hub.